Abstract
In 2006, hypomagnesemia was first described as a complication of proton-pump inhibitors. To address this issue, we systematically reviewed the literature. Hypomagnesemia, mostly associated with hypocalcemic hypoparathyroidism and hypokalemia, was reported in 64 individuals on long-term proton-pump inhibitors. Hypomagnesemia recurred following replacement of one proton-pump inhibitor with another but not with a histamine type-2 receptor antagonist. The association between proton-pump inhibitors and magnesium metabolism was addressed in 14 case-control, cross-sectional studies. An association was found in 11 of them: 6 reports found that the use of proton-pump inhibitors is associated per se with a tendency towards hypomagnesemia, 2 found that this tendency is more pronounced in patients concurrently treated with diuretics, carboplatin, or cisplatin, and 2 found a relevant tendency to hypomagnesemia in patients with poor renal function. Finally, findings likely reflecting decreased intestinal magnesium uptake were observed on treatment with proton-pump inhibitors. Three studies did not disclose any relationship between magnesium metabolism and treatment with histamine type-2 receptor antagonists. In conclusion, proton-pump inhibitors may cause hypomagnesemia. In these cases, switching to a histamine type-2 receptor antagonist is advised.
| Original language | English |
|---|---|
| Article number | 951768 |
| Journal | Gastroenterology Research and Practice |
| Volume | 2015 |
| DOIs | |
| Publication status | Published - 2015 |
Fingerprint
ASJC Scopus subject areas
- Gastroenterology
- Hepatology
Cite this
Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors. / Janett, Simone; Camozzi, Pietro; Peeters, Gabriëlla G A M; Lava, Sebastiano A G; Simonetti, Giacomo D.; Simonetti, Barbara Goeggel; Bianchetti, Mario G.; Milani, Gregorio P.
In: Gastroenterology Research and Practice, Vol. 2015, 951768, 2015.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors
AU - Janett, Simone
AU - Camozzi, Pietro
AU - Peeters, Gabriëlla G A M
AU - Lava, Sebastiano A G
AU - Simonetti, Giacomo D.
AU - Simonetti, Barbara Goeggel
AU - Bianchetti, Mario G.
AU - Milani, Gregorio P.
PY - 2015
Y1 - 2015
N2 - In 2006, hypomagnesemia was first described as a complication of proton-pump inhibitors. To address this issue, we systematically reviewed the literature. Hypomagnesemia, mostly associated with hypocalcemic hypoparathyroidism and hypokalemia, was reported in 64 individuals on long-term proton-pump inhibitors. Hypomagnesemia recurred following replacement of one proton-pump inhibitor with another but not with a histamine type-2 receptor antagonist. The association between proton-pump inhibitors and magnesium metabolism was addressed in 14 case-control, cross-sectional studies. An association was found in 11 of them: 6 reports found that the use of proton-pump inhibitors is associated per se with a tendency towards hypomagnesemia, 2 found that this tendency is more pronounced in patients concurrently treated with diuretics, carboplatin, or cisplatin, and 2 found a relevant tendency to hypomagnesemia in patients with poor renal function. Finally, findings likely reflecting decreased intestinal magnesium uptake were observed on treatment with proton-pump inhibitors. Three studies did not disclose any relationship between magnesium metabolism and treatment with histamine type-2 receptor antagonists. In conclusion, proton-pump inhibitors may cause hypomagnesemia. In these cases, switching to a histamine type-2 receptor antagonist is advised.
AB - In 2006, hypomagnesemia was first described as a complication of proton-pump inhibitors. To address this issue, we systematically reviewed the literature. Hypomagnesemia, mostly associated with hypocalcemic hypoparathyroidism and hypokalemia, was reported in 64 individuals on long-term proton-pump inhibitors. Hypomagnesemia recurred following replacement of one proton-pump inhibitor with another but not with a histamine type-2 receptor antagonist. The association between proton-pump inhibitors and magnesium metabolism was addressed in 14 case-control, cross-sectional studies. An association was found in 11 of them: 6 reports found that the use of proton-pump inhibitors is associated per se with a tendency towards hypomagnesemia, 2 found that this tendency is more pronounced in patients concurrently treated with diuretics, carboplatin, or cisplatin, and 2 found a relevant tendency to hypomagnesemia in patients with poor renal function. Finally, findings likely reflecting decreased intestinal magnesium uptake were observed on treatment with proton-pump inhibitors. Three studies did not disclose any relationship between magnesium metabolism and treatment with histamine type-2 receptor antagonists. In conclusion, proton-pump inhibitors may cause hypomagnesemia. In these cases, switching to a histamine type-2 receptor antagonist is advised.
UR - http://www.scopus.com/inward/record.url?scp=84929649776&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929649776&partnerID=8YFLogxK
U2 - 10.1155/2015/951768
DO - 10.1155/2015/951768
M3 - Article
AN - SCOPUS:84929649776
VL - 2015
JO - Gastroenterology Research and Practice
JF - Gastroenterology Research and Practice
SN - 1687-6121
M1 - 951768
ER -